#1 Clinical Trials Search in Europe

Berzosertib

Berzosertib, also known as M6620 or VX-970, is an investigational drug being studied in various clinical trials for the treatment of different types of cancer. This article explores the ongoing research into berzosertib’s potential as a novel targeted therapy, often used in combination with other cancer treatments. We’ll examine its mechanism of action, the types of cancers being studied, and the preliminary results from several clinical trials.

Table of Contents

What is Berzosertib?

Berzosertib is a new type of cancer drug that is currently being studied in clinical trials. It is also known by other names such as M6620, VX-970, or VX970[7]. Berzosertib belongs to a class of drugs called ATR kinase inhibitors. ATR stands for “ataxia telangiectasia and Rad3-related,” which is a protein that plays an important role in how cells respond to DNA damage[2].

How Does Berzosertib Work?

Berzosertib works by blocking the ATR protein, which is the master regulator of how cells respond to DNA damage and replication stress. When ATR is blocked, cancer cells that are undergoing rapid division and experiencing DNA damage are less able to repair themselves. This can lead to the death of cancer cells[2].

In simpler terms, Berzosertib targets a weakness in cancer cells. Cancer cells often divide rapidly and have unstable DNA. By blocking the ATR protein, Berzosertib makes it harder for these cancer cells to survive and continue growing.

What Cancers Can Berzosertib Treat?

Berzosertib is being studied in clinical trials for several types of cancer, including:

  • Small cell lung cancer (SCLC): A fast-growing type of lung cancer[1]
  • Ovarian cancer: Cancer that begins in the ovaries[3]
  • Urothelial cancer: Cancer that affects the lining of the urinary system[4]
  • Prostate cancer: Cancer that develops in the prostate gland[5]
  • Advanced solid tumors: Various types of cancers that form solid masses[6]

It’s important to note that Berzosertib is still in the research phase and is not yet approved for general use. It is only available through clinical trials at this time.

How is Berzosertib Given?

Berzosertib is typically given as an intravenous (IV) infusion. This means it is delivered directly into the bloodstream through a vein. The exact dosing schedule can vary depending on the specific clinical trial, but some common approaches include:

  • Given on days 2 and 9 of a 21-day cycle[1]
  • Administered on days 2 and 5 of a 21-day cycle[8]
  • Given on days 1, 8, and 15 of a 21-day cycle[6]

The duration of treatment with Berzosertib depends on how well a patient responds to the drug and whether they experience any severe side effects.

Berzosertib in Combination Therapies

Many clinical trials are studying Berzosertib in combination with other cancer treatments. This approach, called combination therapy, can sometimes be more effective than using a single drug. Some combinations being studied include:

  • Berzosertib with Topotecan (another chemotherapy drug) for small cell lung cancer[1]
  • Berzosertib with Gemcitabine for ovarian cancer[3]
  • Berzosertib with Cisplatin and Gemcitabine for urothelial cancer[4]
  • Berzosertib with Carboplatin for prostate cancer[5]
  • Berzosertib with Avelumab (an immunotherapy drug) for various solid tumors[7]

Potential Side Effects

As with all cancer treatments, Berzosertib can cause side effects. The full range of potential side effects is still being studied in clinical trials. Some of the side effects that researchers are monitoring include:

  • Changes in blood cell counts, which could increase the risk of infection or bleeding
  • Fatigue
  • Nausea or vomiting
  • Changes in liver or kidney function

It’s important to remember that not everyone experiences the same side effects, and many side effects can be managed with proper medical care[1][3].

Ongoing Research

Berzosertib is still in the early stages of research, and scientists are working to understand more about how it works and who it might help the most. Some areas of ongoing research include:

  • Testing Berzosertib in different types of cancer
  • Studying how well Berzosertib works in combination with other cancer treatments
  • Identifying which patients are most likely to benefit from Berzosertib treatment
  • Investigating the long-term effects of Berzosertib

For example, one study is looking at whether Berzosertib might be particularly effective in cancers with certain genetic mutations that affect DNA repair[7].

If you’re interested in learning more about Berzosertib or participating in a clinical trial, it’s important to discuss this with your healthcare team. They can provide more information about whether this treatment might be appropriate for your specific situation.

Aspect Details
Drug Name Berzosertib (also known as M6620 or VX-970)
Drug Type ATR kinase inhibitor
Administration Intravenous infusion
Cancer Types Studied Small cell lung cancer, ovarian cancer, urothelial cancer, prostate cancer, advanced solid tumors
Common Combinations Topotecan, gemcitabine, carboplatin, cisplatin, avelumab, sacituzumab govitecan
Key Outcomes Measured Progression-free survival, overall survival, objective response rate, safety and tolerability
Notable Results Promising results in combination therapies, particularly in small cell lung cancer and ovarian cancer trials
Ongoing Research Focus Optimal dosing, combination strategies, biomarkers for patient selection

FAQ

  • What is berzosertib and how does it work? Berzosertib is an ATR kinase inhibitor. It works by blocking enzymes needed for cancer cell growth, potentially stopping tumor cells from dividing and spreading. It is often combined with other cancer treatments to enhance their effectiveness.
  • What types of cancer is berzosertib being studied for? Berzosertib is being investigated for various cancers including small cell lung cancer, ovarian cancer, urothelial cancer, prostate cancer, and other advanced solid tumors. It's being studied both as a single agent and in combination with other treatments.
  • How is berzosertib administered? Berzosertib is typically given as an intravenous (IV) infusion. The dosing schedule varies depending on the specific trial, but it's often administered on certain days within treatment cycles that repeat every 21 or 28 days.
  • What are some common side effects of berzosertib? As with many cancer treatments, berzosertib can cause side effects. These may include fatigue, nausea, and changes in blood cell counts. However, the full safety profile is still being evaluated in clinical trials.
  • How effective is berzosertib in treating cancer? The effectiveness of berzosertib is still being determined through clinical trials. Some studies have shown promising results, particularly when combined with other treatments. However, more research is needed to fully understand its efficacy across different cancer types and patient populations.

Ongoing Clinical Trials on Berzosertib

  • Study on Berzosertib and Gemcitabine for Adults with Advanced or Metastatic Soft-Tissue Leiomyosarcomas

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • ATR kinase inhibitor: A type of drug that blocks the activity of ATR (ataxia telangiectasia and Rad3-related) kinase, an enzyme involved in DNA damage response and cell cycle regulation.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without the disease getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body.

References

  1. https://clinicaltrials.gov/study/NCT04768296
  2. https://clinicaltrials.gov/study/NCT04802174
  3. https://clinicaltrials.gov/study/NCT02595892
  4. https://clinicaltrials.gov/study/NCT02567409
  5. https://clinicaltrials.gov/study/NCT03517969
  6. https://clinicaltrials.gov/study/NCT03309150
  7. https://clinicaltrials.gov/study/NCT04266912
  8. https://clinicaltrials.gov/study/NCT04246111